



## University of Dundee

### FULFIL

Lipworth, Brian J.; Jabbal, Sunny

*Published in:*  
American Journal of Respiratory and Critical Care Medicine

*DOI:*  
[10.1164/rccm.201704-0728LE](https://doi.org/10.1164/rccm.201704-0728LE)

*Publication date:*  
2017

*Document Version*  
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

*Citation for published version (APA):*  
Lipworth, B. J., & Jabbal, S. (2017). FULFIL: an Unmet Need in Chronic Obstructive Pulmonary Disease . American Journal of Respiratory and Critical Care Medicine, 196(8), 1082-1082.  
<https://doi.org/10.1164/rccm.201704-0728LE>

#### General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

#### Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



### FULFIL an unmet need in COPD

Journal:	<i>American Journal of Respiratory And Critical Care Medicine</i>
Manuscript ID	Draft
Manuscript Type:	LE - Letter-to-the-Editor
Date Submitted by the Author:	n/a
Complete List of Authors:	Lipworth, Brian; University of Dundee, Scottish Centre for Respiratory Research Jabbal, Sunny; University of Dundee, Scottish Centre for Respiratory Research
Subject Category:	9.14 COPD: Pharmacological Treatment < LUNG DISEASES
Keywords:	

## **FULFIL an unmet need in COPD**

Authors: Dr Brian J Lipworth and Dr Sunny Jabbal

Affiliation: Scottish Centre for Respiratory Research

School of Medicine

University of Dundee

Ninewells Hospital

Dundee, DD1 9SY

Telephone: +44 (0) 1382 383188

Fax: +44 (0) 1382 383259

Correspondence: [b.j.lipworth@dundee.ac.uk](mailto:b.j.lipworth@dundee.ac.uk)

Word count: 263

To the Editor,

We read with interest the recent data from the FULFIL trial which showed that for both co-primary end points, triple therapy comprising inhaled corticosteroid with long acting beta-agonist and muscarinic antagonist (ICS/LABA/LAMA) was superior to twice daily dual therapy (ICS/LABA) after 24 weeks in patients with COPD (1), confirming the known benefits of dual versus single long acting bronchodilator therapy(2). It was nonetheless impressive that for trough FEV1 at 24 weeks, the mean difference of 171ml was not only statistically significant but also exceeded the minimal clinical important difference (MCID) of 100ml(3), suggesting that the impact of single inhaler triple therapy was clinically relevant. The same was not however true for SGRQ score where the mean difference of 2.2, while statistically significant, was less than the MCID of 4.0. Nonetheless there were 35% significantly fewer exacerbations at the same time point. A real life observational study with time dependent analysis in 2853 patients with COPD over 4.65 years showed a 29% significant reduction in exacerbations requiring oral corticosteroids and 15% significantly fewer hospital admissions conferred by taking once daily tiotropium in addition to twice daily ICS/LABA as separate inhalers (4). Moreover such triple therapy was associated with 35% significantly lower all cause mortality. The question remains as to whether equally impressive differences would be seen when comparing single inhalers containing ICS/LABA/LAMA and LABA/LAMA, particularly since LABA/LAMA has been shown to be superior to ICS/LABA (5). This will be important to know since combinations containing ICS are

more likely to be associated with pneumonia, especially with fluticasone furoate which has prolonged lung retention (6).

For Review Only

## References

1. Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, Ludwig-Sengpiel A, Mohindra R, Tabberer M, Zhu CQ, Pascoe SJ. FULFIL Trial: Once-Daily Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med* 2017;10.1164/rccm.201703-0449OC.
2. Buhl R, Maltais F, Abrahams R, Bjermer L, Derom E, Ferguson G, Flezar M, Hebert J, McGarvey L, Pizzichini E, Reid J, Veale A, Gronke L, Hamilton A, Korducki L, Tetzlaff K, Waitere-Wijker S, Watz H, Bateman E. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). *Eur Respir J* 2015; 45: 969-979.
3. Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal clinically important differences in pharmacological trials. *Am J Respir Crit Care Med* 2014; 189: 250-255.
4. Short PM, Williamson PA, Elder DH, Lipworth SI, Schembri S, Lipworth BJ. The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting beta-agonist therapy in COPD. *Chest* 2012; 141: 81-86.
5. Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF, Investigators F. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. *N Engl J Med* 2016;10.1056/NEJMoa1516385.
6. Allen A, Bareille PJ, Rousell VM. Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man

compared with inhaled fluticasone propionate. *Clin Pharmacokinet* 2013; 52: 37-42.

For Review Only